TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Shares Outstanding

Last Annual Value

40.54M

3-Year CAGR

11%

5-Year CAGR

10%

10-Year CAGR

11%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of shares-outstanding

TMDX · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
40.54M
7.6%8.0%10.8% 
67.14M
8.5%14.0%N/A
57.19M
5.7%4.3%4.6%
151.80M
1.0%-0.1%-0.7%
81.70M
1.5%N/AN/A
84.39M
13.1%12.0%N/A
128.00M
-3.4%-3.7%-1.5%
114.40M
11.7%45.2%N/A
262.39M
5.8%8.0%N/A
163.37M
-3.2%-2.1%21.4%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
182.42M
14.0%15.8%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69